{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:58:36Z","timestamp":1768323516205,"version":"3.49.0"},"reference-count":50,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S1092852923002249_sec1\"><jats:title>Background<\/jats:title><jats:p>Vortioxetine has demonstrated dose-dependent efficacy in patients with major depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg\/day. This analysis further explored the clinical relevance of the more rapid and greater improvement in depressive symptoms observed with vortioxetine 20 mg\/day vs 10 mg\/day.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852923002249_sec2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Analysis of pooled data from six short-term (8-week), randomized, placebo-controlled, fixed-dose studies of vortioxetine 20 mg\/day in patients with MDD (<jats:italic>N<\/jats:italic> = 2620). Symptomatic response (\u226550% decrease in Montgomery\u2013\u00c5sberg Depression Rating Scale [MADRS] total score), sustained symptomatic response, and remission (MADRS total score \u226410) were assessed by vortioxetine dosage (20 or 10 mg\/day).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852923002249_sec3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>After 8 weeks, 51.4% of patients receiving vortioxetine 20 mg\/day had achieved symptomatic response vs 46.0% of those receiving vortioxetine 10 mg\/day (<jats:italic>P<\/jats:italic> &lt; .05). Significantly more patients achieved symptomatic response vs placebo from week 2 onwards for vortioxetine 20 mg\/day and from week 6 onwards for vortioxetine 10 mg\/day (both <jats:italic>P<\/jats:italic> \u2264 .05). Sustained response was achieved from week 4 for 26.0% of patients receiving vortioxetine 20 mg\/day vs 19.1% of those receiving vortioxetine 10 mg\/day (<jats:italic>P &lt;<\/jats:italic> .01), increasing to 36.0% and 29.8%, respectively, over the 8-week treatment period (<jats:italic>P &lt;<\/jats:italic> .05). At week 8, 32.0% of patients receiving vortioxetine 20 mg\/day were in remission vs 28.2% of those receiving vortioxetine 10 mg\/day (<jats:italic>P<\/jats:italic> = .09). Rates of adverse events and treatment withdrawal were not increased during the week following vortioxetine dose up-titration to 20 mg\/day.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852923002249_sec4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>Vortioxetine 20 mg\/day provides more rapid and more sustained symptomatic response than vortioxetine 10 mg\/day in patients with MDD, without compromising tolerability.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852923002249","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T09:38:47Z","timestamp":1681810727000},"page":"693-701","source":"Crossref","is-referenced-by-count":13,"title":["Clinical benefits of vortioxetine 20 mg\/day in patients with major depressive disorder"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3605-7223","authenticated-orcid":false,"given":"Michael C.","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-1976","authenticated-orcid":false,"given":"Michael","family":"Adair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-9406","authenticated-orcid":false,"given":"Ioana","family":"Florea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-0853","authenticated-orcid":false,"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"S1092852923002249_r26","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000936"},{"key":"S1092852923002249_r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2017.12.025"},{"key":"S1092852923002249_r38","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12565"},{"key":"S1092852923002249_r10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06314"},{"key":"S1092852923002249_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.07.008"},{"key":"S1092852923002249_r9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.07m03780"},{"key":"S1092852923002249_r40","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116628440"},{"key":"S1092852923002249_r37","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145714000546"},{"key":"S1092852923002249_r42","doi-asserted-by":"publisher","DOI":"10.1021\/jm101459g"},{"key":"S1092852923002249_r43","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.189068"},{"key":"S1092852923002249_r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.10.011"},{"key":"S1092852923002249_r4","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx081"},{"key":"S1092852923002249_r44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00810.x"},{"key":"S1092852923002249_r19","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2019705"},{"key":"S1092852923002249_r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.04.017"},{"key":"S1092852923002249_r3","first-page":"e1","article-title":"Functional recovery in major depressive disorder: focus on early optimized treatment","volume":"18","author":"Habert","year":"2016","journal-title":"Prim Care Companion CNS Disord."},{"key":"S1092852923002249_r1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02091.x"},{"key":"S1092852923002249_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.05.048"},{"key":"S1092852923002249_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.03.007"},{"key":"S1092852923002249_r22","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.622"},{"key":"S1092852923002249_r34","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000018"},{"key":"S1092852923002249_r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2017.07.003"},{"key":"S1092852923002249_r35","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3839-0"},{"key":"S1092852923002249_r46","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01285-w"},{"key":"S1092852923002249_r24","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12956"},{"key":"S1092852923002249_r48","doi-asserted-by":"publisher","DOI":"10.1124\/mol.118.113530"},{"key":"S1092852923002249_r45","first-page":"86","article-title":"Imaging the serotonin transporter during major depressive disorder and antidepressant treatment","volume":"32","author":"Meyer","year":"2007","journal-title":"J Psychiatry Neurosci."},{"key":"S1092852923002249_r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.074"},{"key":"S1092852923002249_r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.07.015"},{"key":"S1092852923002249_r36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09335"},{"key":"S1092852923002249_r39","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3282f2b4d6"},{"key":"S1092852923002249_r7","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2017.1306082"},{"key":"S1092852923002249_r31","unstructured":"31. H. Lundbeck A\/S Brintelllix (vortioxetine): summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brintellix-epar-product-information_en.pdf. Updated September 2021. Accessed March 30, 2023."},{"key":"S1092852923002249_r18","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1546691"},{"key":"S1092852923002249_r6","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716659417"},{"key":"S1092852923002249_r29","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2750"},{"key":"S1092852923002249_r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.07.001"},{"key":"S1092852923002249_r15","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00138-4"},{"key":"S1092852923002249_r13","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S340309"},{"key":"S1092852923002249_r5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115581093"},{"key":"S1092852923002249_r14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0805"},{"key":"S1092852923002249_r23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118788826"},{"key":"S1092852923002249_r30","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04109-5"},{"key":"S1092852923002249_r33","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32832a8eb2"},{"key":"S1092852923002249_r32","unstructured":"32. Takeda Pharmaceuticals America, Inc. Trintellix (vortioxetine): highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/204447s021s022lbl.pdf. Updated January 2021. Accessed March 30, 2023."},{"key":"S1092852923002249_r25","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S296451"},{"key":"S1092852923002249_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.07.005"},{"key":"S1092852923002249_r16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09918"},{"key":"S1092852923002249_r49","doi-asserted-by":"publisher","DOI":"10.1007\/s11930-019-00205-y"},{"key":"S1092852923002249_r27","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20r13682"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852923002249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T14:22:25Z","timestamp":1702390945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852923002249\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1092852923002249"],"URL":"https:\/\/doi.org\/10.1017\/s1092852923002249","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}